ABLi Therapeutics Launches with Novel Parkinson’s Therapy

ABLi Therapeutics (ABLi) has officially launched. 

The company is dedicated to developing therapies that target conditions caused by the activation of Abelson Tyrosine Kinases (c-Abl kinases), with Parkinson’s disease and related disorders as its primary focus.

Risvodetinib has shown encouraging results in clinical studies. In a recent placebo-controlled trial (NCT05424276), it was the first monotherapy to improve quality of life in patients with untreated Parkinson’s disease while also demonstrating a reduction in disease-related pathology. 

The treatment is taken orally once daily and has been designed to interfere with the mechanisms believed to drive disease progression. It is currently protected by intellectual property rights extending beyond 2036.

ABLi’s lead product candidate, risvodetinib (ABLi-148009), is being developed as a potential disease-modifying treatment. Unlike existing therapies that manage symptoms, risvodetinib aims to address the root causes of Parkinson’s disease.

The company has also established a portfolio of second-generation product candidates based on its proprietary RAMP™ drug development platform. This platform has produced a range of small-molecule inhibitors that are selective for non-receptor c-Abl kinases. 

These new compounds are reported to offer improved potency and safety compared to current commercially available options and are capable of reaching therapeutic levels in both the brain and peripheral tissues.

ABLi is supported by a scientific advisory board comprising experts in Parkinson’s and related neurological conditions, guiding the company's efforts to bring innovative therapies to patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!